Orchestrating an Innovation Renaissance: Addressing the Structural Limitations of Virginia’s Research and Development Tax Credit Framework for High-Growth SMEs

1. Introduction

The Commonwealth of Virginia stands at a decisive economic crossroads as it navigates the post-sunset landscape of its primary innovation incentives. For over a decade, the Virginia Research and Development Expenses Tax Credit and the Major Research and Development Expenses Tax Credit served as the dual pillars of the state’s strategy to foster a knowledge-based economy.¹ However, the statutory expiration of these credits on January 1, 2025, coupled with a fundamental design flaw in the eligibility thresholds, has created a significant hurdle for the Commonwealth’s most dynamic economic drivers: high-growth small and medium-sized enterprises (SMEs). The current framework utilizes a rigid $5 million qualified research expense (QRE) threshold to bifurcate corporate participants into two distinct programs, an arbitrary benchmark that effectively excludes mid-market innovators from accessing the higher credit tiers necessary to compete on a global scale.¹ This whitepaper examines the systemic impact of these restrictive thresholds, analyzes the competitive disadvantages they impose relative to neighboring jurisdictions, and proposes structural reforms to align Virginia’s fiscal policy with the realities of modern, capital-intensive research sectors such as biotechnology, cybersecurity, and aerospace.

2. The Structural Architecture of Virginia’s Research Incentives

To understand the policy failure inherent in the $5 million threshold, one must first examine the origin and mechanical operation of the Commonwealth’s R&D tax credit regime. Virginia was a relatively late entrant into the regional competition for research-driven business investment, establishing its first credit in 2011, nearly thirty years after pioneering states like Minnesota.¹ The resulting framework was divided into two programs with divergent objectives, funding pools, and eligibility requirements. The Research and Development Expenses Tax Credit (RDC), codified under Virginia Code § 58.1-439.12:08, was designed to provide a refundable “safety net” for smaller entities and startups.⁶ Conversely, the Major Research and Development Expenses Tax Credit (MRD), codified under § 58.1-439.12:11, aimed to incentivize large-scale industrial investments by established corporations.³

The standard RDC allows a credit for taxpayers with $5 million or fewer in Virginia qualified research expenses.¹ The credit is typically calculated as 15 percent of the first $300,000 of QREs that exceed a historical base amount, or 20 percent if the research is conducted in collaboration with a Virginia public or private institution of higher education.¹ While the refundability of this credit offers critical liquidity to pre-profit startups, the absolute maximum benefit is strictly capped at $45,000 per company, or $60,000 for university-partnered research.¹ This cap has remained largely stagnant despite the soaring costs of technical labor and laboratory equipment in Virginia’s high-tech corridors.⁸

Table 1: Comparison of Virginia Research Incentive Tiers

Source: ¹

The MRD serves as the second tier of this framework, reserved exclusively for those firms that exceed the $5 million spending mark.¹ Unlike the RDC, the MRD is non-refundable but offers a ten-year carry-forward provision to offset future tax liabilities.¹ While the credit rate of 10 percent of incremental spending is theoretically generous, the program has historically been plagued by oversubscription and subsequent proration, leaving many large-scale investors receiving only a fraction of their certified credit amount.⁷

3. The “Innovation Valley of Death”: Threshold Impact on SMEs

The primary policy issue stems from the $5 million “gatekeeper” threshold, which creates an unintended fiscal cliff for high-growth SMEs. In capital-intensive industries such as biotechnology or autonomous systems development, $5 million in annual research spending does not define a “large” corporation; rather, it often characterizes a mid-stage startup (Series B or C) that is scaling its operations but has not yet reached commercial profitability.¹³ Under the current system, a firm spending $4.8 million on research is confined to the RDC and its $45,000 cap, resulting in an effective credit rate of less than 1 percent of its total investment.¹ If that same firm increases its spending to $5.1 million, it suddenly qualifies for the MRD, where it could theoretically claim a credit of hundreds of thousands of dollars.¹

This binary structure creates a “dead zone” where SMEs are punished for growing but are not yet large enough to fully utilize the benefits of a non-refundable credit.⁷ Many of Virginia’s most promising high-growth companies—particularly those in the life sciences sector—remain pre-profit for a decade or more while navigating regulatory hurdles.¹⁴ For these firms, the shift from a refundable RDC to a non-refundable MRD is a “net loss” in immediate cash flow, even if the theoretical credit amount is higher.⁷ This dynamic discourages incremental spending increases that would push a firm just over the $5 million mark, thereby stunting the growth of the Commonwealth’s middle-market innovation base.

Furthermore, the $5 million threshold fails to account for the unique economic composition of Virginia’s technology sectors. In the cybersecurity and software-as-a-service (SaaS) industries, which are centered in Northern Virginia, the primary research expense is highly compensated human capital.¹⁶ A firm with 25 senior security engineers, each earning an average of $200,000, reaches the $5 million threshold on payroll alone before accounting for any cloud infrastructure or supply costs.¹⁷ In the biotechnology sector, the median investment required for an FDA-approved biologic is estimated at over $300 million, with annual research spending for even small Phase II trials often exceeding the $5 million threshold.¹⁴ By setting the “Major” benchmark at $5 million, the Commonwealth is effectively treating mid-sized companies like global conglomerates, while offering them an incentive structure that is poorly suited to their cash-flow requirements.

Table 2: Industry Sector Breakdown and Threshold Impact

Source: ¹⁴

4. Regional Competition and the Risk of Capital Flight

The restrictive nature of Virginia’s thresholds is compounded by the aggressive incentive strategies of neighboring and peer states. Maryland, Virginia’s most direct competitor in the “DMV” (District-Maryland-Virginia) region, offers an R&D tax credit that distinguishes between “Basic” and “Growth” categories but links refundability specifically to firm size (50 or fewer employees) rather than a rigid spending dollar amount.⁷ This allows Maryland to target its most liquid incentives at small businesses regardless of whether they have a high-spending year due to a specific project.

In the northern tier, Massachusetts and New York have established themselves as global biotech and tech leaders by offering significantly more flexible credit regimes. Massachusetts provides a 10 percent credit on QREs with an indefinite carry-forward for portions of the credit disallowed by tax liability caps.²⁰ More critically, Massachusetts allows “Life Sciences” designated companies to receive refundable research credits, recognizing that pre-profit innovation is the lifeblood of that sector.²⁰ New York offers a refundable Life Sciences Research and Development Tax Credit that provides up to 20 percent for companies with fewer than ten employees and 15 percent for those with more, capped at a substantial $500,000 per year.²³

In contrast, Virginia’s $45,000 cap on the refundable RDC is one of the lowest in the nation among states that offer such incentives.⁵ When a high-growth Virginia SME reaches $4.9 million in spending and realizes its next hire will push it into a non-refundable credit regime with no immediate cash benefit, the decision to relocate to Maryland or New York becomes a fiduciary necessity. This “brain drain” and “capital flight” are not theoretical risks; the 2022 Joint Legislative Audit and Review Commission (JLARC) report noted that while Virginia performs well on basic measures of high-tech performance, it lags in measures of innovation vitality and entrepreneurship, such as the number of fast-growth companies per million residents.⁹

5. The 2025 Sunset and the Current Legislative Crisis

The policy challenge is currently exacerbated by a period of extreme statutory uncertainty. Under House Bill 1518, signed in 2024, the Virginia R&D tax credits were extended only through tax years beginning before January 1, 2025.² During the 2025 Regular Session of the General Assembly, House Bill 1969 was introduced to extend these sunsets and modernize the provisions.² However, HB 1969 failed to pass out of a conference committee on February 22, 2025, leaving the Commonwealth without an active state-level R&D credit for the 2025 tax year and beyond.²

This legislative failure has created a “tax cliff” that disproportionately affects SMEs. While larger corporations can rely on their 10-year carry-forward from previous years’ MRD awards, SMEs utilizing the refundable RDC have no such cushion.¹ The absence of the credit in 2025 means that pre-profit startups will lose a vital source of operating cash flow, potentially leading to layoffs or the suspension of critical research projects.² The 2026 General Assembly session is widely expected to attempt a reinstatement of these credits, but a simple renewal of the existing, flawed thresholds would miss a historic opportunity to fix the underlying structural problems that have limited the program’s effectiveness.²

Table 3: Legislative Timeline of Virginia R&D Sunsets

Source: ²

The failure to extend these credits also comes at a time when the federal tax environment has become more hostile to research. Changes to IRC Section 174 now require firms to amortize R&D expenses over five years rather than expensing them immediately, a change that significantly increases the tax burden on innovative firms.²⁶ Without a state-level credit to offset these federal changes, Virginia’s competitive position continues to erode.

6. Proposed Solution I: The Graduated Step-Rate Reimbursement Structure

The most comprehensive solution to the threshold problem is the adoption of a “step-rate” reimbursement structure for a unified Research and Development Tax Credit. This model, which was specifically recommended by JLARC in its 2022 evaluation, would eliminate the binary $5 million threshold in favor of a graduated system that provides higher levels of support for the first several million dollars of research spending.⁹

Under this proposal, the distinction between the “RDC” and “MRD” would be dissolved. Instead, all firms would apply for a single Virginia Research Credit. The credit rate would be tiered to prioritize the “initial” spending of all companies, which research shows is where tax incentives have the most significant marginal impact on business behavior.¹² For example, the Commonwealth could offer a 12 percent credit for the first $2 million of qualified research expenses, an 8 percent credit for expenses between $2 million and $7 million, and a 5 percent credit for all expenses exceeding $7 million.¹²

This structure would fundamentally benefit high-growth SMEs in several ways:

• Access to Higher Tiers: Mid-market firms spending $3 million or $4 million would no longer be capped at a nominal $45,000. They would receive a credit proportional to their actual investment, bridging the gap between small-scale and large-scale operations.
• Predictability and Scaling: As a firm grows its research budget, it would move through the tiers predictably without hitting a “cliff” where the entire mechanism of its incentive changes.¹²
• Budgetary Protection: By lowering the credit rate for the highest brackets of spending, the Commonwealth protects the general fund from being overwhelmed by a handful of mega-corporations, ensuring that the total credit pool is distributed more equitably across the innovation ecosystem.⁹

Hypothetical Step-Rate Calculation for a High-Growth SME

Consider an SME in the cybersecurity sector with $4 million in Virginia QREs. Under the old system, this firm is capped at $45,000.¹ Under the proposed step-rate model:

Table 4: Step-Rate Calculation Example ($4M QRE)

This reform would increase the benefit for this specific firm by over 800 percent, providing a meaningful fiscal incentive to expand its research team within the Commonwealth. To ensure this does not result in an unmanageable fiscal impact, the General Assembly could maintain an overall program cap but utilize the step-rate model to determine the allocation of credits within that cap.⁹

7. Proposed Solution II: Threshold Realignment and RDC Cap Indexing

A second, more targeted solution involves the immediate realignment of the $5 million threshold and an expansion of the standard RDC’s per-company cap. If the General Assembly prefers to maintain two distinct programs to separate refundable and non-refundable incentives, it should lower the “Major” threshold from $5 million to $1 million.¹ This would allow high-growth SMEs to “graduate” into the Major R&D program much earlier in their lifecycle, accessing the non-capped (though prorated) pool of the MRD.³

Simultaneously, the Commonwealth should increase the per-company cap for the standard RDC from $45,000 to $150,000 and index this cap to the Consumer Price Index (CPI).²⁹ The current $45,000 cap was established over a decade ago; in today’s market, it barely covers the employer-side costs of one senior researcher.⁸ By tripling the cap, Virginia would align its small-business incentive with the reality of modern research costs, making it a competitive alternative to the more generous programs in Maryland and New York.⁷

To further enhance the impact on high-growth SMEs, the state should introduce an “R&D Intensity” multiplier. Firms that spend more than 20 percent of their total operating budget on research should be eligible for a 50 percent increase in their individual company cap.³⁴ This targets the state’s limited fiscal resources at the most innovative, research-centric companies rather than firms that conduct routine technical work as a minor part of their business model.

Table 5: Threshold Realignment & Cap Indexing Comparison

Source: ¹

8. Implementation and Fraud Prevention: Ensuring Accountability

Expanding the reach and value of R&D tax credits necessitates a robust administrative framework to prevent fraud, waste, and abuse. The 2022 JLARC evaluation noted that the Virginia Department of Taxation already manages a relatively complex application process that requires more supporting details than the federal credit.¹ However, as the stakes increase for high-growth SMEs, the following enhancements should be implemented to protect the Commonwealth’s resources.

First, the Department of Taxation should mandate a third-party “CPA Attestation” for all R&D credit claims exceeding $50,000. Under this requirement, an independent Certified Public Accountant would be required to verify that the claimed expenses were actually incurred, are “qualified” under the IRC Section 41 definition, and have a direct “nexus” to research activities performed within Virginia.³⁵ This shifts the initial burden of verification to the private sector and ensures that only legitimate, well-documented claims reach the Department for final certification.³⁸

Second, the Commonwealth should adopt a “Project-Level Narrative” requirement for all applications. Currently, many firms submit aggregated expense data that makes it difficult for auditors to verify the “experimentation” and “uncertainty” components of the four-part test.¹⁸ By requiring a concise technical narrative for each major research project, the state can more effectively distinguish between true innovation and routine quality control or market research, both of which are excluded from the credit.³⁵

Finally, the state should implement a “Recapture Provision” for companies that receive significant R&D credits but relocate their headquarters or the majority of their research staff outside the Commonwealth within three years of receiving the award. This ensures that the state’s investment in innovation results in long-term local economic activity rather than subsidizing the growth of a firm that ultimately takes its intellectual property and jobs to a competitor state.²

9. Cost Analysis: Fiscal Outlay as a Strategic Investment

Any expansion of tax credits must be analyzed through the lens of both immediate fiscal impact and long-term economic return. The 2022 JLARC report characterized the “Return in Revenue” (RIR) of R&D tax credits as “negligible” or “low,” generating approximately 4 to 5 cents in direct tax revenue for every dollar spent.⁹ However, this narrow metric fails to capture the broader “Social Return” and “Spillover Effects” that are the primary justification for innovation subsidies.⁴¹

Research by the Congressional Research Service (CRS) and various academic institutions suggests that the social return on R&D—the benefit to the economy as a whole—is two to four times higher than the private return to the individual firm.⁴¹ In Virginia, these spillovers are evident in the rapid growth of the “Data Center Alley” and the burgeoning “Bio-Tech” hubs in Richmond and Roanoke.¹⁶ For every dollar the state invests in research-driven firms, it supports an ecosystem of high-wage jobs, attracts additional federal research grants, and builds a cluster of specialized suppliers and service providers.⁸

The proposed reforms—merging the credits into a step-rate structure and increasing the SME cap—would likely require an increase in the total annual credit pool from the current ~$32 million to approximately $60 million.² While this represents a $28 million annual increase in “tax expenditure,” it is a modest sum compared to the $2 billion the industry saved through the data center sales tax exemption in FY 2025 alone.¹⁰ Furthermore, by attracting just five additional Series B startups that would otherwise have located in Maryland or North Carolina, the state would likely recoup the increased cost through the personal income taxes paid by hundreds of high-earning researchers and engineers.¹³

Table 6: Fiscal and Economic Impact Projections

Source: ⁹

10. The Imperative of Action: Consequences of the Status Quo

The consequences of maintaining the $5 million threshold and failing to modernize the R&D credit framework are severe and multifaceted. First, Virginia faces a “Stagnation of the Mid-Market.” While the state successfully attracts massive “trophy” projects like Amazon HQ2,³⁴ its ability to cultivate its own homegrown tech giants is limited by a fiscal environment that ignores companies in the crucial $1 million to $10 million spending range.⁹

Second, the “Regional Brain Drain” will accelerate. As high-growth SMEs in Northern Virginia and the Hampton Roads area realize that Maryland offers a more logical and lucrative path for scaling their research, they will move their operations across the border.⁷ This is not merely a loss of tax revenue; it is a loss of the Commonwealth’s most valuable asset: its human capital. The thousands of researchers, scientists, and engineers who work for these firms are the primary drivers of consumption, property tax revenue, and community leadership in Virginia.⁸

Finally, the Commonwealth risks “Sectoral Vulnerability.” By failing to support a diverse array of mid-sized innovators, Virginia remains overly dependent on a few massive industries—primarily federal contracting and data centers.¹⁶ If the data center market matures or if federal spending shifts away from Virginia-based contractors, the lack of a robust, independent innovation sector will leave the state’s economy exposed to a profound downturn.¹⁶

11. Conclusion: A Vision for Virginia’s Innovation Economy

The restrictive $5 million threshold for the Major Research and Development Expenses Tax Credit is an anachronism that no longer serves the interests of the Commonwealth’s high-growth SMEs. In a global economy where innovation is the primary currency of growth, Virginia cannot afford a fiscal policy that traps its most promising companies in a “valley of death” between startup support and corporate scale.

The 2026 General Assembly session offers a unique opportunity to not only reinstate the expired R&D credits but to fundamentally restructure them for the 21st century. By adopting a graduated step-rate reimbursement model or lowering the Major threshold while expanding the SME cap, the Commonwealth can create a seamless “innovation pipeline” that supports companies from their first lab bench to their global headquarters. This is not merely a matter of tax policy; it is a strategic investment in the long-term resilience, diversity, and competitiveness of the Virginia economy. The cost of reform is manageable, the safeguards are available, and the potential for a sustained innovation renaissance is immense.

Obras citadas

1. Virginia Research and Development Tax Credits – Endeavor Advisors, fecha de acceso: marzo 18, 2026, https://www.endeavoradvisors.com/virginia-rd-tax-credit/
2. Virginia R&D Tax Credit: 2025 Sunset Implications and 2026 …, fecha de acceso: marzo 18, 2026, https://www.cbh.com/insights/articles/virginia-rd-tax-credit-changes-impact-on-businesses/
3. § 58.1-439.12:11. Major research and development expenses tax credit – Virginia Law, fecha de acceso: marzo 18, 2026, https://law.lis.virginia.gov/vacode/title58.1/chapter3/section58.1-439.12:11/
4. Major Research and Development Expenses Tax Credit Guidelines – Virginia Tax, fecha de acceso: marzo 18, 2026, https://www.tax.virginia.gov/major-research-and-development-expenses-tax-credit-guidelines
5. Appendix F: R&D tax incentives by state – JLARC, fecha de acceso: marzo 18, 2026, https://jlarc.virginia.gov/pdfs/oversight/ED_initiatives/SciTech%20Appendix%20F.pdf
6. Virginia R&D Tax Credit Explained for Businesses – Swanson Reed, fecha de acceso: marzo 18, 2026, https://www.swansonreed.com/research-tax-credit/virginia/
7. The Virginia And Maryland R&D Tax Credits – Tri-Merit, fecha de acceso: marzo 18, 2026, https://tri-merit.com/latest-updates/the-virginia-maryland-rd-tax-credits-refundable-state-credit-incentivizes-startups-and-small-businesses/
8. Governor Glenn Youngkin Announces $6.2 Million in Growth and Opportunity Virginia Grants | DHCD, fecha de acceso: marzo 18, 2026, https://www.dhcd.virginia.gov/governor-glenn-youngkin-announces-62-million-growth-and-opportunity-virginia-grants
9. Science and Technology Incentives – National Conference of State Legislatures, fecha de acceso: marzo 18, 2026, https://documents.ncsl.org/wwwncsl/Fiscal/evaluationDB/ScienceandTechnologyIncentives.pdf
10. Economic Development Incentives 2024 – JLARC – Virginia.gov, fecha de acceso: marzo 18, 2026, https://jlarc.virginia.gov/pdfs/reports/Rpt597.pdf
11. Virginia R&D Tax Credit Changes: What You Need To Know | Alvarez & Marsal, fecha de acceso: marzo 18, 2026, https://www.alvarezandmarsal.com/insights/virginia-rd-tax-credit-changes-what-you-need-know
12. Science and Technology Incentives – JLARC – Virginia.gov, fecha de acceso: marzo 18, 2026, https://jlarc.virginia.gov/pdfs/presentations/Rpt562Pres.pdf
13. The Series B Pipeline Looks Refreshingly Diversified – Crunchbase News, fecha de acceso: marzo 18, 2026, https://news.crunchbase.com/venture/data-series-b-startup-funding-ai-defense-health/
14. Biotech Startup Valuation: Series A & B Benchmarks and Trends 2026 – Qubit Capital, fecha de acceso: marzo 18, 2026, https://qubit.capital/blog/biotech-series-a-b-valuation-benchmarks
15. Research and development investments for biologics independently developed by US biotechnology startups, 2017–2023 – PMC, fecha de acceso: marzo 18, 2026, https://pmc.ncbi.nlm.nih.gov/articles/PMC12290397/
16. GOVA Region 7 Growth and Diversification Plan 2025 – DHCD – Virginia.gov, fecha de acceso: marzo 18, 2026, https://www.dhcd.virginia.gov/sites/default/files/DocX/gova/region-seven/gova-r7-gd-plan-25.pdf
17. RD576 – The Commonwealth Cyber Initiative: Fiscal Year 2025 Annual Report, fecha de acceso: marzo 18, 2026, https://rga.lis.virginia.gov/Published/2025/RD576
18. R&D tax credits guide for CPAs – ADP, fecha de acceso: marzo 18, 2026, https://www.adp.com/resources/articles-and-insights/articles/r/r-and-d-tax-credit-guide-for-cpas.aspx
19. States Spend Big on R&D Tax Credits. Are They Paying Off? – Governing, fecha de acceso: marzo 18, 2026, https://www.governing.com/finance/states-spend-big-on-r-d-tax-credits-are-they-paying-off
20. Massachusetts R&D Tax Credits, fecha de acceso: marzo 18, 2026, https://www.striketax.com/state-rd-credits/massachusetts-r-d-tax-credits
21. Massachusetts Research Tax Credit | Mass.gov, fecha de acceso: marzo 18, 2026, https://www.mass.gov/info-details/massachusetts-research-tax-credit
22. Massachusetts R&D Tax Credit, Exclusive benefits for you – Hito LLC, fecha de acceso: marzo 18, 2026, https://hitollc.com/massachusetts-rd-tax-credit/
23. Life sciences research and development tax credit – Tax.NY.gov, fecha de acceso: marzo 18, 2026, https://www.tax.ny.gov/pit/credits/life-sciences-research-and-development-tax-credit.htm
24. The New York Guide to State Tax Incentives | Gusto, fecha de acceso: marzo 18, 2026, https://gusto.com/resources/states/new-york/ny-tax-incentives
25. Science and Technology Incentives – Virginia JLARC, fecha de acceso: marzo 18, 2026, https://jlarc.virginia.gov/pdfs/reports/Rpt562-1.pdf
26. Virginia R&D Tax Credits – Strike Tax Advisory, fecha de acceso: marzo 18, 2026, https://www.striketax.com/state-rd-credits/virginia-rd-tax-credits
27. VA HB1969 | 2025 | Regular Session – LegiScan, fecha de acceso: marzo 18, 2026, https://legiscan.com/VA/bill/HB1969/2025
28. HB1969 – 2025 Regular Session – LIS, fecha de acceso: marzo 18, 2026, https://lis.virginia.gov/bill-details/20251/HB1969
29. General Assembly 2026 – Virginia Retail Federation, fecha de acceso: marzo 18, 2026, https://virginiaretailfederation.com/general-assembly-2026/
30. The 2026 General Assembly session wraps with no budget, special session on the horizon, fecha de acceso: marzo 18, 2026, https://cardinalnews.org/2026/03/14/the-2026-general-assembly-session-wraps-with-no-budget-special-session-on-the-horizon/
31. R&D Tax Credits: What Businesses Need to Know | Newburg & Company, fecha de acceso: marzo 18, 2026, https://newburg.com/rd-tax-credit-what-business-known-to-know/
32. TAX BULLETIN 26-1 Virginia Department of Taxation – February 20, 2026, fecha de acceso: marzo 18, 2026, https://www.tax.virginia.gov/sites/default/files/inline-files/tb-26-1-date-of-irc-conformity-advanced.pdf
33. Recent Research: Unravelling the paradox of R&D tax credits – SSTI, fecha de acceso: marzo 18, 2026, https://ssti.org/blog/recent-research-unravelling-paradox-rd-tax-credits
34. SME vs Large Company R&D Claims Compared – Zest Tax, fecha de acceso: marzo 18, 2026, https://www.zest.tax/sme-large-company-rd-claims-comparison/
35. Mistakes to Avoid When Choosing an R&D Tax Credit Consultant – Boast, fecha de acceso: marzo 18, 2026, https://www.boast.ai/blog/rd/mistakes-to-avoid-when-choosing-an-rd-tax-credit-consultant
36. Why Taxpayers Are Trusting CPAs With R&D Tax Credit Claims | Cherry Bekaert, fecha de acceso: marzo 18, 2026, https://www.cbh.com/insights/articles/why-taxpayers-are-trusting-cpas-with-rd-tax-credit-claims/
37. Why Pass-Through Entities Need Expert Guidance to Claim R&D Tax Credits – KBKG, fecha de acceso: marzo 18, 2026, https://www.kbkg.com/research-and-development/why-pass-through-entities-need-expert-guidance-to-claim-rd-tax-credits
38. Guidance Documents | Virginia Tax, fecha de acceso: marzo 18, 2026, https://www.tax.virginia.gov/guidance-documents
39. Audits | Virginia Tax, fecha de acceso: marzo 18, 2026, https://www.tax.virginia.gov/audits
40. Audit techniques guide: Credit for Increasing Research Activities (i.e. Research Tax Credit) IRC § 41* – Qualified research activities | Internal Revenue Service, fecha de acceso: marzo 18, 2026, https://www.irs.gov/businesses/audit-techniques-guide-credit-for-increasing-research-activities-ie-research-tax-credit-irc-ss-41-qualified-research-activities
41. The Federal Research and Development (R&D) Tax Credit – EveryCRSReport.com, fecha de acceso: marzo 18, 2026, https://www.everycrsreport.com/reports/R48848.html
42. R&D Tax Credits that Improve ROI – Patsnap, fecha de acceso: marzo 18, 2026, https://www.patsnap.com/resources/blog/rd-tax-credits-that-improve-roi/
43. Virginia Tech generates $4.7 billion in economic impact across Virginia, new report shows, fecha de acceso: marzo 18, 2026, https://news.vt.edu/articles/2026/02/cm-economicimpact-2026.html
44. The 10 most important things that happened in Virginia’s 2026 legislative session, fecha de acceso: marzo 18, 2026, https://www.henricocitizen.com/the-10-most-important-things-that-happened-in-virginias-2026-legislative-session/
45. Understanding tax differences between Maryland and Virginia | Beltway Movers DMV, fecha de acceso: marzo 18, 2026, https://www.beltwaymovers.com/understanding-tax-differences-between-maryland-and-virginia/
46. Virginia General Assembly proposes to eliminate sales and use tax exemption for data centers | DLA Piper, fecha de acceso: marzo 18, 2026, https://www.dlapiper.com/en-us/insights/publications/2026/03/virginia-general-assembly-proposes-to-eliminate-sales-and-use-tax-exemption-for-data-centers